Cerluten
A Khavinson-class ultrashort peptide bioregulator proposed to protect neural tissue and support cognition through gene-expression regulation.
Cerluten is a synthetic short peptide of the Khavinson bioregulator tradition, investigated for neuroprotective and anti-aging effects in neuronal cell populations. It is proposed to enter target cells via amino acid transporters and to modulate transcriptional activity in aging or damaged neural tissue. Evidence is limited and derives largely from Khavinson-series and class-level preclinical work rather than independent Western clinical trials.
Class
Synthetic ultrashort peptide (Khavinson-class bioregulator)
Routes
Oral, Subcutaneous
Category
Cognitive & Nootropic
Researched benefits
What it's studied for
Neuroprotection
Proposed to protect aging or damaged neuronal cell populations against neurodegeneration by regulating gene expression in neural tissue. Evidence is class-level and preclinical rather than from dedicated human trials.
Cognitive support
Investigated as a support for attention and general cognitive function within the Khavinson bioregulator framework of tissue-specific transcriptional modulation.
Memory consolidation
Russian clinical reports associate cerluten with improved memory consolidation, though independent peer-reviewed confirmation is lacking.
Anti-aging in neural tissue
Framed as an anti-aging bioregulator that may modulate transcriptional activity in aging neurons, consistent with the broader Khavinson peptide class.
Mechanism
How it works
Cerluten belongs to the Khavinson family of ultrashort regulatory peptides, which are proposed to reach their target cells through amino acid transporter uptake, including proton-coupled oligopeptide transporters (POT) and large amino acid transporters (LAT). Once inside the cell, these peptides are described as translocating to the nucleus and binding chromatin to modulate gene expression.
For cerluten specifically, this mechanism is directed at cerebral and central nervous system tissue. The peptide is proposed to modulate transcriptional activity in aging or damaged neural cells, providing the basis for its investigated neuroprotective and anti-aging effects.
The mechanistic framework is drawn largely from class-level research on Khavinson short peptides rather than from studies isolating cerluten itself. Published reviews characterize the POT/LAT-mediated intracellular transport, nuclear penetration, chromatin binding, and epigenetic gene-expression modulation shared across the peptide class, within which cerluten's neuronal effects are proposed.
Evidence
Research & clinical studies (2)
Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium
Characterizes the cellular uptake of ultrashort Khavinson peptides including cerluten via POT and LAT transporter-mediated mechanisms, with nuclear translocation and chromatin binding underlying their gene-expression regulatory activity.
PMID 35887081Peptide Regulation of Gene Expression: A Systematic Review
Documents that short regulatory peptides (2-7 amino acids) including cerluten penetrate the nucleus, bind chromatin, and modulate gene expression, providing the mechanistic framework for tissue-specific peptide regulatory activity.
PMID 34834147Safety
Side effects & considerations
Contraindications & cautions
- Pregnancy or nursing
Cerluten is generally described as lower risk in research contexts, but individual response varies and safety data are limited. No specific common side effects are documented in the source.
FAQ
Cerluten — common questions
What is Cerluten?
Cerluten is a synthetic short peptide classified as a Khavinson-class bioregulator targeted at cerebral and central nervous system tissue, investigated for neuroprotective and anti-aging properties in neuronal cell populations through proposed gene-expression regulatory mechanisms.
What is Cerluten primarily studied for?
It is studied primarily for neuroprotection, cognitive support, memory, anti-aging, and longevity.
How is Cerluten thought to work?
Like other Khavinson bioregulator peptides, it is proposed to reach target neuronal cells via amino acid transporter uptake (POT and LAT carriers) and to modulate transcriptional activity in aging or damaged neural tissue.
What are the side effects of Cerluten?
The main reported consideration is that it should be avoided during pregnancy or nursing. It is generally described as lower risk in research contexts, but data are limited and individual response varies.
Is Cerluten approved by the FDA?
No. Cerluten has no FDA or EMA approval and is sold as a research-only compound. Independent peer-reviewed clinical trial evidence specific to cerluten is limited.
What does the research show about Cerluten?
Cited reviews characterize the cellular uptake of ultrashort Khavinson peptides including cerluten via POT and LAT transporter mechanisms, demonstrating nuclear translocation and chromatin binding that underlie their gene-expression regulatory activity in brain and nervous system tissue.
